Le Lézard
Classified in: Health
Subjects: NPT, VET

Veterans Guardian Sponsors Samaritan Colony's Annual Fundraiser


PINEHURST, N.C., Nov. 16, 2023 /PRNewswire/ -- Veterans Guardian VA Claim Consulting was a proud sponsor of the Second Annual Benefit for Recovery Event hosted by Samaritan Colony. The community event, which took place at Malcolm Blue Farm in Aberdeen, NC, helped raise over $16,000, which will go towards the continuous effort of supporting those who suffer from addiction.

Earlier in the year, the Veterans Guardian Treatment Scholarship was established at Samaritan Colony in order to support veterans suffering from addiction.

Samaritan Colony has been providing ongoing support to underserved people who suffer from addiction since 1975. Samaritan Colony is a 12-bed nonprofit residential chemical dependency treatment facility for men in Rockingham, NC. They are currently building a 14-bed residential treatment center for women.

"As a company that assists underserved veterans, we are proud to sponsor Samaritan Colony," said Scott Greenblatt, CEO and Founder of Veterans Guardian. "They not only provide shelter, guidance, and support to those looking for a better future, but they bring people together with inspirational events."

At Veterans Guardian, a commitment to community support is a core principle. The company actively supports more than 100 local and national charities, particularly those connected to the military and veterans. This support is manifested through ongoing financial contributions to community-centric charities, the provision of scholarships, and dedicated volunteer efforts.

About Veterans Guardian

Veterans Guardian is a VA Claim Consulting Firm headquartered in Pinehurst, NC, serving clients worldwide. Veterans Guardian works to help Veterans attain the VA Disability benefits they are medically and ethically eligible for as a result of their honorable service in the United States Military. For more information, visit www.VetsGuardian.com

SOURCE Veterans Guardian


These press releases may also interest you

at 07:05
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor...

at 07:05
Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective...

at 07:05
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger...

at 07:05
bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder...

at 07:05
Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter...

at 07:05
Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...



News published on and distributed by: